

ASX Announcement

7 February 2025

Investor webinar invitation

Sydney, Australia – 7 February 2025: Pancreatic cancer treatment device company **OncoSil Medical Limited** (ASX:OSL) (“OncoSil” or “the Company”) will host an investor webinar on Tuesday 11 February 2025.

The webinar will be presented by OncoSil’s Chief Executive Officer & Managing Director, Nigel Lange, and will be followed by a short Q&A session.

In his webinar presentation, Mr Lange will discuss recent developments in the OncoSil™ device’s commercialisation strategy, including:

- An update on the German Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) approval for the Directive for testing the new treatment method: "Endoscopic injection-implantation of 32P-labeled microparticles in unresectable, locally advanced pancreatic tumors."
- The authorisation by the German Institute for the Hospital Remuneration System (InEK) for 120 German hospitals to negotiate funding for the OncoSil™ device classification under the innovation funding (NUB) program with the statutory health insurance (SHI) companies during the annual budget negotiations.
- The receipt of Medical Device Regulation certification from BSI, the EU Notified Body, including the lifting of existing post-market restrictions and its impacts.
- Latest updates about ongoing clinical trials (TRIPP-FFX and PANCOSIL).

OncoSil Medical Investor Webinar Registration Details:

DATE: Tuesday 11 February 2025

TIME: 3.00PM AEDT

FORMAT: Zoom

Links to Reference Documents:

- [G-BA approval received for OncoSil device](#)
- [120 German hospitals entitled to negotiate fee for OncoSil](#)
- [OncoSil Medical receives MDR approval](#)

Please register in advance using the following link:

https://us02web.zoom.us/webinar/register/WN_Otjt_CNpQUazqUdgJPBudw

After registering, you will receive a confirmation email containing information about joining the webinar.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	Mr. Christian Dal Cin CFO & Company Secretary E: c.dalcin@acclime.com T: +61 3 9824 5254	Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 7257 7338
--	--	---

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival¹.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (³²P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

References: 1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>